Regenxbio Inc

RGNX remains in a Stage 2 advance with clear higher highs and higher lows supported by rising short-term EMAs and expanding volume. The active Momentum Breakout signals new demand overwhelming prior supply at resistance. Price is extended above EMAs and in overbought territory, so short-term timing is unclear—execution should be deferred to pullbacks into rising EMA support or the breakout zone. Medium-term bias stays bullish while the long-term trend remains bearish.

• ↑$100M AbbVie milestone from dosing first patient in Phase IIb/III trial.
• ↑RGX202 hit primary endpoints in DMD trial with robust safety.
• ↓Negative earnings yield and weak profitability hinder financial sustainability.